Neumora appoints Joshua Pinto as CEO, narrows Q2 net loss to $43.1M

Neumora Therapeutics, Inc.

Joshua Pinto named CEO and Board member; Paul Berns becomes Executive Chair, effective Aug 14, 2026.
Doron Sagman, M.D., appointed Chief Medical Officer; brings 20+ years of clinical development experience.
Q2 2026 net loss $43.1M vs $52.7M in Q2 2025; R&D $29.3M, G&A $12.9M; cash $116.8M as of June 30, 2026.
Pipeline: NMRA-215 IND Q4 2026, Phase 1 by end 2026; NMRA-511 MAD data Q4 2026 and Phase 2 initiation by end 2026; NMRA-898 Phase 1 data H2 2026.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joshua Pinto

Class III director

NMRA · Neumora Therapeutics, Inc.

Effective: 2026-08-14
Filed: August 14, 2026, 7:13 AM ET

In connection with the Leadership Transition, on August 12, 2026, the Board also approved the appointment of Dr. Pinto as a Class III director, effective as of the Transition Date, to serve for a term expiring at the 2029 Annual Meeting of Stockholders and until his successor is elected and qualified or until his earlier death, resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joshua Pinto was appointed as Class III director at Neumora Therapeutics, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

In connection with the Leadership Transition, on August 12, 2026, the Board also approved the appointment of Dr. Pinto as a Class III director, effective as of the Transition Date, to serve for a term expiring at the 2029 Annual Meeting of Stockholders and until his successor is elected and qualified or until his earlier death, resignation or removal.

View on SEC.gov

Neumora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-350349

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.